Meridian Bioscience Inc. (NSDQ:VIVO) struck an exclusive, world-wide product development and distribution agreement with an Italian diagnostics company that is likely to open doors to new customers in Eastern Europe and Asia.
Meridian Bioscience (NSDQ:VIVO) applied for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system.
Meridian Bioscience Inc. posted first-quarter sales of $42.5 million for the three months ended Dec. 31, 2009, up 23.8 percent compared with $34.3 million during the same period in fiscal 2009. Net earnings rose 10.5 percent to $8.9 million, compared with $8.1 million during Q1 2009:
Press Release
CINCINNATI–(BUSINESS WIRE)–Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: